Prophylaxis  ||| S:0 E:12 ||| NNP
of  ||| S:12 E:15 ||| IN
hepatic  ||| S:15 E:23 ||| JJ
insufficiency  ||| S:23 E:37 ||| NN
after  ||| S:37 E:43 ||| IN
major  ||| S:43 E:49 ||| JJ
hepatic  ||| S:49 E:57 ||| NNS
resections  ||| S:57 E:68 ||| VBP
The  ||| S:68 E:72 ||| DT
article  ||| S:72 E:80 ||| NN
deals  ||| S:80 E:86 ||| NNS
with  ||| S:86 E:91 ||| IN
a  ||| S:91 E:93 ||| DT
problem  ||| S:93 E:101 ||| NN
of  ||| S:101 E:104 ||| IN
prophylaxis  ||| S:104 E:116 ||| NN
of  ||| S:116 E:119 ||| IN
hepatic  ||| S:119 E:127 ||| JJ
insufficiency  ||| S:127 E:141 ||| NN
in  ||| S:141 E:144 ||| IN
oncological  ||| S:144 E:156 ||| JJ
patients  ||| S:156 E:165 ||| NNS
after  ||| S:165 E:171 ||| IN
liver  ||| S:171 E:177 ||| JJ
resections ||| S:177 E:187 ||| NN
.  ||| S:187 E:189 ||| .
We  ||| S:189 E:192 ||| PRP
analyzed  ||| S:192 E:201 ||| VBD
data  ||| S:201 E:206 ||| NNS
of  ||| S:206 E:209 ||| IN
effectiveness  ||| S:209 E:223 ||| NN
and  ||| S:223 E:227 ||| CC
safety  ||| S:227 E:234 ||| NN
of  ||| S:234 E:237 ||| IN
the  ||| S:237 E:241 ||| DT
use  ||| S:241 E:245 ||| NN
of  ||| S:245 E:248 ||| IN
Remaxol  ||| S:248 E:256 ||| NNP
in  ||| S:256 E:259 ||| IN
oncological  ||| S:259 E:271 ||| JJ
patients  ||| S:271 E:280 ||| NNS
with  ||| S:280 E:285 ||| IN
hepatic  ||| S:285 E:293 ||| JJ
metastasis  ||| S:293 E:304 ||| NN
of  ||| S:304 E:307 ||| IN
colorectal  ||| S:307 E:318 ||| JJ
cancer--dynamics  ||| S:318 E:335 ||| NN
of  ||| S:335 E:338 ||| IN
indicators  ||| S:338 E:349 ||| NNS
of  ||| S:349 E:352 ||| IN
cytolysis  ||| S:352 E:362 ||| NN
and  ||| S:362 E:366 ||| CC
cholestasis ||| S:366 E:377 ||| NN
,  ||| S:377 E:379 ||| ,
hepatic  ||| S:379 E:387 ||| JJ
protein  ||| S:387 E:395 ||| NN
synthesis ||| S:395 E:404 ||| NN
,  ||| S:404 E:406 ||| ,
exchange  ||| S:406 E:415 ||| NN
of  ||| S:415 E:418 ||| IN
pigments ||| S:418 E:426 ||| NNS
,  ||| S:426 E:428 ||| ,
pro-  ||| S:428 E:433 ||| JJ
and  ||| S:433 E:437 ||| CC
antioxidant  ||| S:437 E:449 ||| JJ
system  ||| S:449 E:456 ||| NN
and  ||| S:456 E:460 ||| CC
the  ||| S:460 E:464 ||| DT
level  ||| S:464 E:470 ||| NN
of  ||| S:470 E:473 ||| IN
endogen  ||| S:473 E:481 ||| JJ
intoxication  ||| S:481 E:494 ||| NN
in  ||| S:494 E:497 ||| IN
postoperative  ||| S:497 E:511 ||| JJ
period ||| S:511 E:517 ||| NN
.  ||| S:517 E:519 ||| .
Use  ||| S:519 E:523 ||| NN
of  ||| S:523 E:526 ||| IN
Remaxol  ||| S:526 E:534 ||| NNP
allows  ||| S:534 E:541 ||| VBZ
decreasing  ||| S:541 E:552 ||| VBG
the  ||| S:552 E:556 ||| DT
duration  ||| S:556 E:565 ||| NN
of  ||| S:565 E:568 ||| IN
postoperative  ||| S:568 E:582 ||| JJ
rehabilitation  ||| S:582 E:597 ||| NN
and  ||| S:597 E:601 ||| CC
intensive  ||| S:601 E:611 ||| JJ
care  ||| S:611 E:616 ||| NN
unit  ||| S:616 E:621 ||| NN
staying ||| S:621 E:628 ||| VBG
.  ||| S:628 E:630 ||| .
